Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) and Cellectis (NASDAQ:CLLS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Institutional and Insider Ownership
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Achilles Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
| Cellectis | -234.39% | -74.55% | -22.65% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Achilles Therapeutics and Cellectis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
Achilles Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 464.52%. Given Cellectis’ stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Achilles Therapeutics.
Valuation & Earnings
This table compares Achilles Therapeutics and Cellectis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.87 |
| Cellectis | $29.07 million | 2.37 | -$101.06 million | ($1.30) | -0.95 |
Achilles Therapeutics has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectis beats Achilles Therapeutics on 9 of the 13 factors compared between the two stocks.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
